Industry
EMEA Plans To Include Parallel Imports In Future Post-Marketing Tests
August 2008 | Industry NewsThe European Medicines Agency (EMEA) plans to screen parallel imports as part of changes to the body's sampling and testing programme for centrally authorised medicinal products (CAPs). This follows proposals in January 2008 for using a risk-based approach for selecting which medicines would be screened in
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
